Poseida Therapeutics Stock News

The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.

Poseida Therapeutics (NASDAQ:PSTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The brokerage presently has a $7.75 target price on the stock. Zacks Investment Researchs target price indicates a potential upside of 15.67% from the stocks current price. According to Zacks, []

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics (NASDAQ:PSTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for []

Zacks Investment Research downgraded shares of Poseida Therapeutics (NASDAQ:PSTX) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of []

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Director Life Sciences Holdings L. Malin bought 18,365 shares of the firms stock in a transaction that occurred on Wednesday, December 1st. The shares were acquired at an average cost of $6.85 per share, for a total transaction of $125,800.25. The acquisition was disclosed in a legal filing with the Securities []

Poseida Therapeutics (NASDAQ:PSTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Thursday, Zacks.com reports. The firm currently has a $7.75 price objective on the stock. Zacks Investment Researchs target price points to a potential upside of 9.62% from the companys current price. []

Poseida Therapeutics (NASDAQ:PSTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions [] The post Poseida Therapeutics (NASDAQ:PSTX) Stock Rating Lowered by Zacks Investment Research appeared first on ETF Daily News .

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Director Life Sciences Holdings L. Malin acquired 27,251 shares of the firms stock in a transaction on Friday, November 26th. The shares were acquired at an average price of $6.81 per share, with a total value of $185,579.31. The purchase was disclosed in a legal filing with the Securities & Exchange []

California State Teachers Retirement System decreased its stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 20.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,657 shares of the companys stock after selling 10,285 shares during the period. California State Teachers Retirement System []

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Director Life Sciences Holdings L. Malin bought 11,057 shares of the stock in a transaction that occurred on Monday, November 29th. The stock was acquired at an average price of $6.89 per share, for a total transaction of $76,182.73. The purchase was disclosed in a filing with the Securities & Exchange []

Zacks Investment Research cut shares of Poseida Therapeutics (NASDAQ:PSTX) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions []

Poseida Therapeutics (NASDAQ:PSTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Thursday, Zacks.com reports. The firm currently has a $7.75 target price on the stock. Zacks Investment Researchs price target suggests a potential upside of 13.14% from the stocks previous close. According to []

The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is ques